Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra) today announced that Orsini is now the pharmacy partner for OLPRUVA® (sodium phenylbutyrate) for oral suspension. OLPRUVA® is a prescription medicine used along with certain therapies, including changes in diet, for long-term management of certain adult and pediatric patients with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Visit OLPRUVA-Prescribing-Information.pdf (olpruva.com) to view the full Prescribing Information, including Important Safety Information.
Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug
ViiV Healthcare and Medicines Patent Pool (MPP) have signed sublicence agreements with Aurobindo Pharma, Cipla Limited, and Viatris Inc (NASDAQ:VTRS) – through its subsidiary Mylan – to…
